Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Toll-like receptor–driven and interleukin-1 (IL-1) receptor–driven inflammation mediated by
IL-1 receptor–associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN…

Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …

Background Continued SARS-CoV-2 infections and COVID-19-related hospitalizations
highlight the need for effective anti-viral treatments in the outpatient setting. In a descriptive …

… Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Ximena Graber; Gerard Acloque;
Yessica Sachdeva; Joseph A. Bocchini; Anita Kohli; Bari Kowal; Thomas DiCioccio; …

Background: REGEN-COV (casirivimab and imdevimab) antibody cocktail reduced SARS-CoV-2
viral load in descriptive analyses of the first 275 Covid-19 outpatients in the phase 1/2 …

There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized
patients but few for patients who are not sick enough to be hospitalized. Monoclonal …

The phases of SARS-CoV-2 infection may be viewed along a spectrum. 1 Following
exposure, patients may have asymptomatic infection in which they test positive for the virus by …

Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-19,
butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …